Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
about
Inflammatory breast cancer: clinical progress and the main problems that must be addressedUpdate on inflammatory breast cancerFirst description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three casesShort- and long-term cause-specific survival of patients with inflammatory breast cancer.Inflammatory breast cancer: what we know and what we need to learnIn vivo lymphatic imaging of a human inflammatory breast cancer model.Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancerTrastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentCirculating tumor cells in newly diagnosed inflammatory breast cancer.Survival of women with inflammatory breast cancer: a large population-based studyPrognostic significance of HER-2 status in women with inflammatory breast cancerNeoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Locally advanced prostate cancer: a population-based study of treatment patternsInflammatory breast cancer: is it really a separate entity?A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapyNitrative and oxidative stress in toxicology and disease.Breast cancer: beyond the cutting edge.Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.Biology and management of inflammatory breast cancer.Overview of preoperative radiochemotherapy in breast cancer: past or future?ACR appropriateness criteria® locally advanced breast cancer.When and how do I use neoadjuvant chemotherapy for breast cancer?UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Immediate Reconstruction in Inflammatory Breast Cancer: Challenging Current Care.Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report.Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
P2860
Q21195182-30A73912-5329-4DA4-B01D-F90EE58EF5CEQ24797853-BC45EE10-CDF3-4152-A3C6-D3D8283B194EQ24805938-39469CD4-2C3B-4C86-B899-81D252328338Q24817154-31D9E03C-7B56-420D-87AC-E20FB84089CCQ27028128-C49E5001-9BE1-4D37-BE3F-8E52CC71564EQ30596741-A80F954C-69D9-4D83-92F7-BAFB41D1BC08Q33382437-FF4BD39C-E0EB-48AE-8717-E8801C415538Q33702336-4C3346A4-9A3B-4ECE-91FE-156CFD6C79B4Q33796162-28F0E25B-5A3C-4077-812E-452A0C34B103Q33829270-E0CB48D7-D6BE-4AB5-B8FE-5779BCDB1966Q34753009-80EA1966-B574-4770-BE19-052DA1F13F8AQ34782298-E7586239-32DD-4D7A-84AE-A6C00EC6FE98Q34990356-F46C3383-DEE3-43D0-86BB-DECFFC91807CQ35017523-C2D3C0C0-DE58-43F1-8F17-416811002FF6Q35052773-0F2822E0-D982-4F23-B8FB-8A8332BC2215Q35608330-765E48E2-B309-4F0B-A3C5-BFBEF59178BEQ35624765-709DA898-6EA7-4DA3-8552-A96210EC3FE2Q35667692-ABAA5A7E-CF7C-468A-AD16-FAEDD6AFE38AQ35850867-BBD7BF2C-BC70-40B1-8FC7-5875DC062E8DQ35939285-8E0DD9D0-1FA8-4ED8-BA10-938038EDC845Q36243278-3B737ABB-0058-4649-AB9F-F7D74BD0F640Q36502730-A532DE0D-093D-4436-8F01-99C2DE0E265AQ36611240-D9179FF7-1E6E-4C54-90BB-B821DDA1C043Q36615222-FDED0328-6F3A-4389-9050-C9FAFDDD0D38Q36642955-E42519E4-B335-4399-A2FC-4A2E555902E7Q36751784-23E8D711-47A5-407D-87A6-02D7643FA390Q37015722-B475324F-C382-480F-B6E9-79A5FB2381F2Q37259756-D0E2A744-0B34-45CA-B1C4-6AAA77023A9FQ37402818-9D013486-F04A-4BA5-8441-F0F8BC6D87A7Q37598890-4900EBEF-7DAA-4949-9BFB-83BE841226CAQ37687112-04575E1C-8B11-4D2C-A518-315E92F3BC5EQ37687382-E5917864-6302-423C-9628-EAA960543F11Q37903139-6207E579-C3E7-4A18-A634-02987D6C85E8Q37929856-4BDB5CBC-48C1-4EFB-9927-43A3F8FC33D7Q38168757-1DA4672C-A1FE-4926-81DA-5BCDAD96A0B6Q38412031-46FF74AF-01FB-42C8-BC02-04FABBDA5F6AQ38683638-CE2ED0F4-06CD-46E3-871A-05D569FC90EEQ38957313-B9D58C48-3C27-4C1F-B00B-C49681A4B0DAQ39370791-3BB8B4A4-FC29-4605-B6E0-DBD4872DCBF8Q39691131-1B5C66D3-7209-45A6-928F-95699DFD02A0
P2860
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Combined-modality treatment of ...... M. D. Anderson Cancer Center.
@en
type
label
Combined-modality treatment of ...... M. D. Anderson Cancer Center.
@en
prefLabel
Combined-modality treatment of ...... M. D. Anderson Cancer Center.
@en
P2093
P356
P1476
Combined-modality treatment of ...... M. D. Anderson Cancer Center.
@en
P2093
Hortobagyi GN
McNeese MD
Singletary SE
Theriault RL
P2888
P304
P356
10.1007/S002800050664
P577
1997-01-01T00:00:00Z
P6179
1037613049